 |
| September
17, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Dr. Manish Arora, Founder and CEO,
LinusBio |
| In
this CEO Q&A, Dr. Arora explains the
insight that launched LinusBio, what sets
the company’s hair-based platform apart
from other diagnostic approaches, the
milestones and challenges shaping its
growth from academic research to
commercial product, and where he sees
exposome science heading. More |
|
|
 |
|
One Partner For Your Entire
Vivarium. Research Ready From Day
One. |
|
Learn More
→ |
|
|
- Acelot: Initiation of Dosing in Phase Ia
Clinical Trial of ACE-2223, a First-in-Class
Oral Small Molecule Targeting Aggregated
TDP-43 in Amyotrophic Lateral Sclerosis (ALS)
More
- Genentech: Lunsumio-Based Regimen
Significantly Improves Progression-Free
Survival in Follicular Lymphoma in Phase III
CELESTIMO Study More
- Gilead: Accelerates Global Access
Planning for Investigational Once-Yearly
Lenacapavir for HIV Prevention More
More*
- Lunai Bioworks: Demonstrates AI
Chemical-Risk Screening for Generative AI
More
- Mission Bio: Launches Tapestri Triomics for
Simultaneous DNA, RNA, and Protein Analysis at
Single-Cell Resolution More
- Orca
Bio: Publication of TREGZI Long-Term Overall
Survival Data in Transplantation and Cellular
Therapy More
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Agilent: Cash Dividend of 25.5 Cents per
Share More
- Annexon: Inducement Grants to New Employees
Under Nasdaq Listing Rule 5635(c)(4) More
- AN2 Therapeutics: Inducement Grants Under
Listing Rule 5635(c)(4) More
- Biotech Movers September 16, 2026: Tempest
TPST +59% on In Vivo CAR-T Deal; Xenetic XBIO
-49% on Santersus Merger More
- Cognita Imaging: Receives $1.29 Million FDA
Contract to Test New Approach to Evaluating
Generative AI in Radiology More
- More on RegCell Banking $66 Million to Take
Nobel-winning Treg Work Into Clinic More*
More
- Novo, Anthropic Sign Deal to Apply AI to
Drug Discovery More*
More
- Tempest Therapeutics (TPST) Stock Climbs
Over 66% After Hours: Here's Why More
|
|
- Big4Bio CEO Weekly Q&A: Dr.
Manish Arora, Founder and CEO, LinusBio More
- Biotech & Pharma Updates | September 16,
2026
More
- Charles River Celebrates Thirty
Years of Biotech Innovation More
- Gladstone Institutes:
Rethinking ‘Exhausted’ T Cells - Gilbert
Herrera Named Inaugural Ellen & Bernard
Marson Fellow More
- Human Brain Cells Transplanted Into Mice
in ‘Most Extensive’ Integration Ever More*
More*
- More on Cellares Inking New Cell Therapy
Customer
More*
More
- More on Twist Bioscience Securing Data
Pipeline Role in Eli Lilly TuneLab Ecosystem More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- When Drug Development Becomes
Personal: Meg Gill’s Mission to Find a
Treatment for Her Daughter More
|
|
- AI is Changing the Talent Biotech Companies
Compete to Hire More
- Anixa Biosciences: Appoints UPenn's Dr.
Carmen Guerra to Cancer Business Advisory
Board More
- OPPORTUNITY: Chief Financial Officer,
Boston/San Diego More
- OPPORTUNITY: SVP, Regulatory and Quality
Assurance, Boston/San Diego More
- OPPORTUNITY: Head of Global Research &
Development, Columbia, MD More
- QT Imaging: Appoints Imaging Industry
Veteran Dr. Mark Winkler as Chief Medical
Officer More
- Slone Partners: Behind the Search’ -
A Conversation with George Quinn, Partner,
Fractional Talent More
- Slone Partners: ICYMI - How to Keep Your
Highest Performers Engaged More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: SFBay Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:SFBay,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
